Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

Purpose Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk factors and outcomes of patients who develop ICI-induced hepatitis (ICIH). Methods We utilized an institutional database of patients with advance...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2023-05, Vol.149 (5), p.2235-2242
Main Authors: Miah, Abdul, Tinoco, Gabriel, Zhao, Songzhu, Wei, Lai, Johns, Andrew, Patel, Sandip, Li, Mingjia, Grogan, Madison, Lopez, Gabrielle, Husain, Marium, Hoyd, Rebecca, Mumtaz, Khalid, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Spakowicz, Daniel, Otterson, Gregory A., Presley, Carolyn J., Owen, Dwight H.
Format: Article
Language:English
Subjects:
Adverse events
Cancer Research
CTLA-4 protein
Female
Hematology
Hepatitis
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - adverse effects
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Neoplasms - drug therapy
Oncology
PD-1 protein
Retrospective Studies
Review
Risk Factors
Survival
Terminology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk factors and outcomes of patients who develop ICI-induced hepatitis (ICIH). Methods We utilized an institutional database of patients with advanced cancers treated with ICI to identify patients with ICIH. irAEs were graded using the Common Terminology Criteria for Adverse Events v4. Overall survival (OS) was calculated from the date of ICI to death from any cause or the date of the last follow-up. OS with 95% confidence intervals were estimated using the Kaplan–Meier method and stratified by the occurrence of ICIH. Results We identified 1096 patients treated with ICI. The most common ICIs were PD1/L1 ( n  = 774) and CTLA-4 inhibitors ( n  = 195). ICIH occurred among 64 (6%) patients: severity was 
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-022-04340-3